8/12
08:03 am
ngne
Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $51.00 to $49.00. They now have a "buy" rating on the stock.
Low
Report
Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $51.00 to $49.00. They now have a "buy" rating on the stock.
8/9
07:30 am
ngne
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Low
Report
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
8/7
07:30 am
ngne
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
7/2
07:30 am
ngne
Neurogene to Participate in BMO Genetic Medicines Summit
Medium
Report
Neurogene to Participate in BMO Genetic Medicines Summit
7/1
07:30 am
ngne
Neurogene Announces Addition to Russell 3000® Index
High
Report
Neurogene Announces Addition to Russell 3000® Index
6/27
08:00 am
ngne
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $65.00 price target on the stock.
Medium
Report
Neurogene Inc. (NASDAQ: NGNE) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating and a $65.00 price target on the stock.